



US010188652B2

(12) **United States Patent**
Moline et al.

(10) **Patent No.:** **US 10,188,652 B2**

(45) **Date of Patent:** **Jan. 29, 2019**

(54) **COMPOSITIONS AND METHODS FOR TREATING INSOMNIA**

(71) Applicant: **Eisai R&D Management Co., Ltd.**,
Tokyo (JP)

(72) Inventors: **Margaret Moline**, Woodcliff Lake, NJ (US); **Gina Pastino**, Woodcliff Lake, NJ (US); **Yurie Akimoto**, Kakamigahara (JP); **Yasuhiro Zaima**, Kakamigahara (JP); **Nobuya Suzuki**, Kakamigahara (JP); **Nobuo Yoshida**, Kakamigahara (JP)

(73) Assignee: **Eisai R&D Management Co., Ltd.**,
Tokyo (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **15/519,676**

(22) PCT Filed: **Oct. 21, 2015**

(86) PCT No.: **PCT/JP2015/080304**

§ 371 (c)(1),

(2) Date: **Apr. 17, 2017**

(87) PCT Pub. No.: **WO2016/063995**

PCT Pub. Date: **Apr. 28, 2016**

(65) **Prior Publication Data**

US 2017/0252342 A1 Sep. 7, 2017

Related U.S. Application Data

(60) Provisional application No. 62/067,443, filed on Oct. 23, 2014.

(51) **Int. Cl.**

A61K 31/506 (2006.01)

A61K 9/00 (2006.01)

(Continued)

(52) **U.S. Cl.**

CPC **A61K 31/506** (2013.01); **A61K 9/0053** (2013.01); **A61K 9/2018** (2013.01);

(Continued)

(58) **Field of Classification Search**

CPC .. **A61K 31/506**; **A61K 9/0053**; **A61K 9/2018**; **A61K 9/2054**; **A61K 9/4858**; **A61K 9/4866**

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,935,814 A 8/1999 Bergsma et al.
6,001,963 A 12/1999 Bergsma et al.

(Continued)

FOREIGN PATENT DOCUMENTS

JP 10-229887 9/1998
JP 10-327888 12/1998

(Continued)

OTHER PUBLICATIONS

Clinical pharmacokinetic studies in pharmaceuticals, Jun. 2001, Downloaded from the internet on 018/18/2011) <http://www.nihs.go.jp/phar/material/material2/CIPkEng011122.pdf>.*

(Continued)


Primary Examiner — Savitha M Rao

(74) *Attorney, Agent, or Firm* — Fish & Richardson P.C.

(57) **ABSTRACT**

In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.

15 Claims, 2 Drawing Sheets



- (51) **Int. Cl.**
A61K 9/20 (2006.01)
A61K 9/48 (2006.01)
- (52) **U.S. Cl.**
 CPC **A61K 9/2054** (2013.01); **A61K 9/48**
 (2013.01); **A61K 9/4858** (2013.01); **A61K**
9/4866 (2013.01)

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,020,157	A	2/2000	Bergsma et al.
6,166,193	A	12/2000	Yanagisawa
6,309,854	B1	10/2001	Bergsma et al.
2008/0076771	A1	3/2008	Reiter et al.
2010/0261644	A1	10/2010	DeFossa et al.
2012/0095031	A1*	4/2012	Terauchi C07D 401/12 514/269
2012/0165339	A1	6/2012	Terauchi et al.

FOREIGN PATENT DOCUMENTS

JP	10-327889	12/1998
JP	11-178588	7/1999
JP	06-328057	12/2006
WO	WO 96/034877	11/1996
WO	WO 2005/118548	12/2005
WO	WO 2007/105177	9/2007
WO	WO 2007/129188	11/2007
WO	WO 2008/031772	3/2008
WO	WO 2008/038251	4/2008
WO	WO 2008/069997	6/2008
WO	WO 2008/081399	7/2008
WO	WO 2009/039942	4/2009
WO	WO 2009/047723	4/2009

OTHER PUBLICATIONS

Bettica et al., "Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist," *Journal of Psychopharmacology*, vol. 26, No. 8, GB, Jul. 5, 2011, p. 1058-p. 1070, XP055473159.

European Search Report in European Patent Application No. 15851934, dated May 18, 2018, 9 pages.

International Search Report and Written Opinion for International Patent Application No. PCT/JP2015/080304 dated Jan. 26, 2016.

Vermeeren, "Residual Effects of Hypnotics Epidemiology and Clinical Implications", *CNS Drugs* 2004; 18 (5): 297-328.

Yamadera, "Recent progress in development of hypnotic drugs", *Japanese Journal of Clinical Medicine*, Feb. 1, 1998, vol. 56, No. 2, p. 245-250 (with partial English translation).

Search Results, *ClinicalTrials.gov*, Aug. 15, 2018.

[No Author Listed], "2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects", *ClinicalTrials.gov*, Aug. 28, 2012, E2006-A001-002.

[No Author Listed], "A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006", *ClinicalTrials.gov*, Nov. 1, 2011, E2006-A001-001.

[No Author Listed], "A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion", *ClinicalTrials.gov*, Mar. 13, 2014, E2006-A001-004.

[No Author Listed], "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia", *ClinicalTrials.gov*, Nov. 27, 2013, E2006-G000-201.

[No Author Listed], "A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorex-

[No Author Listed], "A Study to Determine the Effect of a High-Fat Meal on the Rate and Extent of E2006 Absorption in Healthy Subjects", *ClinicalTrials.gov*, Mar. 17, 2014, E2006-A001008.

[No Author Listed], "A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects", *ClinicalTrials.gov*, Jan. 17, 2014, E2006-A001-003.

[No Author Listed], "A Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects", *Clinical Study Report*, Apr. 17, 2015, 12 pages.

[No Author Listed], "An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects", *ClinicalTrials.gov*, Jan. 27, 2014, E2006-A001-007.

[No Author Listed], "Long-term Study of Lemborexant in Insomnia Disorder", *ClinicalTrials.gov*, Nov. 2, 2016, E2006-G000-303.

[No Author Listed], "Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule Formulations", *ClinicalTrials.gov*, Aug. 28, 2012, E2006-A001-005.

[No Author Listed], "Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia", *ClinicalTrials.gov*, Dec. 23, 2016, E2006-G000-202.

[No Author Listed], "Study of Lemborexant-Alcohol Interaction in Healthy Subjects", *ClinicalTrials.gov*, Mar. 30, 2018, E2006-A001-009.

[No Author Listed], "Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)", *ClinicalTrials.gov*, May 26, 2016, E2006-G000-304.

[No Author Listed], "Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects", *ClinicalTrials.gov*, Mar. 1, 2018, E2006-A001-012.

[No Author Listed], "Study to Evaluate the Effect of 2 Dosage Strengths of E2006 on a Multiple Sleep Latency Test in Subjects With Insomnia Disorder", *ClinicalTrials.gov*, Jan. 29, 2015, E2006-A001-107.

[No Author Listed], "Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects", *ClinicalTrials.gov*, Oct. 22, 2015, E2006-E044-106.

[No Author Listed], "Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects", *ClinicalTrials.gov*, Feb. 21, 2018, E2006-A001-104.

[No Author Listed], "Study to Evaluate the Pharmacokinetics of Lemborexant and its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment", *ClinicalTrials.gov*, Feb. 22, 2018, E2006-A001-105.

[No Author Listed], "Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea", *ClinicalTrials.gov*, Mar. 21, 2018, E2006-A001-102.

[No Author Listed], "Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older", *ClinicalTrials.gov*, Jan. 2, 2017, E2006-A001-108.

Beuckmann, "Development of Lemborexant: A Novel Sleep/Wake Regulator for the Treatment of Insomnia", *The 43rd Annual Meeting of Japanese Society of Sleep Research*, Jul. 11-13, 2018.

Borgland et al., "Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine," *Neuron*, 49:589-601 (2006).

Brisbare-Roch et al., "Promotion of sleep by targeting the orexin system in rats, dogs and humans," *Nat. Med.*, 13:150-155 (2007).

Chemelli et al., "Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation," *Cell*, 98:437-451 (1999).

D.A. Prober et al., "26 The Journal of Neuroscience", 2003, p. 13400-p. 13410.

(56)

References Cited**OTHER PUBLICATIONS**

Decision to Grant JP 2012-500752 dated Feb. 28, 2012 (in Japanese).

Dorffner et al., "Effect of almorexant treatment on sleep variables in patients with primary insomnia compared with healthy controls," *European Neuropsychopharmacology*, 20(Suppl 3):S252-S253 (2007).

E Mignot et al., "5 Nature Neuroscience Supplement", 2002, p. 1071-p. 1075.

English translation of the allowed claims in JP 2012-500752 dated Feb. 28, 2012.

IDA et al., "Possible involvement of orexin in the stress reaction in rats," *Biochem. Biophys. Res. Commun.*, 270:318-323 (2000).

International Search Report and Written opinion of PCT/JP2011/071325 dated Oct. 18, 2011 (English Translation).

International Search Report and Written opinion of PCT/JP2011/071325 dated Oct. 18, 2011 (in Japanese).

Moline et al., "Dual Orexin Receptor Antagonist Lemborexant (E2006) Shows Efficacy on Sleep Initiation and Maintenance on Sleep Diary Measures in Phase 2 Study," Poster, The 29th Annual Meeting of the Associated Professional Sleep Societies, LLC (APSS), Jun. 6-10, 2015.

Murphy et al., "Preliminary Efficacy of E2006, a Novel Dual Orexin Receptor Antagonist, for the Treatment of Insomnia Disorder," Poster, SLEEP 2014, the 28th Annual Meeting of the Associated Professional Sleep Societies, LLC (APSS), May 31-Jun. 4, 2014.

Murphy et al., "A Phase 1 Study in Healthy Subjects of the Safety and Tolerability of E2006, a Novel Dual Orexin Receptor Antagonist, for the Treatment of Insomnia Disorder," Poster, SLEEP 2014, the 28th Annual Meeting of the Associated Professional Sleep Societies, LLC (APSS), May 31-Jun. 4, 2014.

Murphy et al., "Dual Orexin Receptor Antagonist Lemborexant (E2006) Shows Equivalent Efficacy in Men and Women in Phase 2 Study," Poster, SLEEP 2015, the annual meeting of the Associated Professional Sleep Societies LLC (APSS), Jun. 10, 2015.

Murphy et al., "Effects of Lemborexant on Sleep Architecture in Subjects with Insomnia Disorder," Poster, SLEEP 2016, the 30th annual meeting of the Associated Professional Sleep Societies LLC (APSS), Jun. 11-15, 2016.

Murphy et al., "Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study", *Journal of Clinical Sleep Medicine*, Nov. 15, 2017 13(11):1289-1299.

Pastino et al., "Pharmacokinetics of Lemborexant (E2006): Relationship to Efficacy and Safety," Poster, SLEEP 2015, the 29th Annual Meeting of the Associated Professional Sleep Societies, LLC (APSS), Jun. 6-10, 2015.

Pastino et al., "Lemborexant Does Not Affect the QT interval: high-precision QT analysis from early clinical studies," Poster, 2015 Annual Meeting of the American College of Clinical Pharmacology (ACCP), Sep. 27-29, 2015.

Pinner et al., "Effects of Lemborexant on Sleep Maintenance in the Latter Half of the Night," Poster, SLEEP 2016, the 30th annual meeting of the Associated Professional Sleep Societies LLC (APSS), Jun. 11-15, 2016.

Pinner et al., "Lemborexant Effects on Sleep Maintenance in the Second Half of the Night," Poster, The 2017 Annual Scientific Meeting of the American Geriatrics Society (AGS), May 18-20, 2017.

Request for Expedited Examination of JP 2012-500752 dated Jan. 18, 2012 (English translation).

Request for Expedited Examination of JP 2012-500752 dated Jan. 18, 2012 (in Japanese).

Richey et al., "Pharmacological Advances in the Treatment of Insomnia," *Curr Pharm Des.* 17(15):1471-75 (2011).

Sakurai et al., "Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior," *Cell*, 92:573-585 (1998).

Satlin et al., "Dual Orexin Receptor Antagonist E2006 Shows Efficacy on Sleep Initiation and Sleep Maintenance in Phase 2 Study," Poster, ACNP 2014, the 53rd Annual Meeting of the American College of Neuropsychopharmacology, Dec. 7-11, 2014.

Shoblock et al., "Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement," *Psychopharmacology*, 215:191-203 (2011).

Vermeeren et al., "Results From an On-Road Driving Performance Study in Non-elderly and Elderly Healthy Subjects With Dual Orexin Receptor Antagonist Lemborexant," Poster, SLEEP 2018, the 32nd annual meeting of the Associated Professional Sleep Societies LLC (APSS), Jun. 2-6, 2018.

Winrow et al., "Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure," *Neuropharmacology*, 58:185-194 (2010).

Office Action in Israeli Patent Application No. 251759, dated Oct. 17, 2018, 5 pages (with English Translation).

Submission Document in Brazilian Patent Application No. BR112017007063-4, dated Sep. 24, 2018, 16 pages. (English Translation).

Submission Document in European Patent Application No. 15851934.8, dated Nov. 26, 2018, 10 pages.

* cited by examiner

FIG. 1




FIG. 2





FIG. 3



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.